Cargando…
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria
BACKGROUND AND OBJECTIVE: In patients with mild-to-moderate COVID-19 and at high risk of progression, casirivimab/imdevimab and bamlanivimab/etesivimab were utilized in Umbria from late April to November 2021. This period was characterized by an initial prevalence of alpha (B1.1.1.7) and its progres...
Autores principales: | Schiaroli, Elisabetta, De Socio, Giuseppe Vittorio, Gidari, Anna, Malincarne, Lisa, Benedetti, Sara, Lanzi, Alessandra, Bastianelli, Sabrina, Pierucci, Sara, Busti, Chiara, Fagotti, Benedetta, Vicenti, Ilaria, Zazzi, Maurizio, Francisci, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266464/ https://www.ncbi.nlm.nih.gov/pubmed/35865399 http://dx.doi.org/10.4084/MJHID.2022.050 |
Ejemplares similares
-
Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2
por: Gidari, Anna, et al.
Publicado: (2022) -
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
por: Gidari, Anna, et al.
Publicado: (2022) -
Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Gidari, Anna, et al.
Publicado: (2022) -
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
por: Gidari, Anna, et al.
Publicado: (2021) -
Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy
por: Schiaroli, Elisabetta, et al.
Publicado: (2021)